Tvardi Therapeutics

TVRD

Biotechnology · Healthcare

Price

$3.20

+0.12 (+3.90%)

Market Cap

$30.0M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+452.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.4M (2021) → 7.8M (2025)

Tvardi Therapeutics is a small biotechnology company focused on developing drugs to treat cancer. It works on therapies that target a protein called STAT3, which plays a role in helping cancer cells survive and grow. The company is in the clinical-stage, meaning its drugs are still being tested in humans and have not yet been approved for sale.

Tvardi makes no product revenue right now. It funds its research through investor capital and grants while it runs clinical trials. The company operates primarily in the United States and is very small, with a market cap near zero. Its potential edge lies in its focus on STAT3 inhibition, a target that has been difficult for other companies to drug effectively. The main risk is that clinical trials may fail, and like most early-stage biotechs, the company will need to raise more money to keep operating, which can dilute existing shareholders.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-40.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$18M/ year

↓ Declining (-45% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

35.2%ownership

Insiders own a meaningful stake in the company

Cash Runway

~13 months

$25M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Tvardi Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-48.6%

Weak — -48.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial